VEGFA and mucositis: Additionally, we found that atezolizumab and bevacizumab extended the PFS and OS of NRAS mutant patients to levels similar to those of wild‐type patients, and NRAS mutant mucosal melanoma exhibiting enhanced angiogenesis feature with elevated VEGFA expression.